FDA Cracks Down on Compounded GLP-1 Weight Loss Drugs
FDA plans to restrict non-approved compounded GLP-1 drugs sold by Hims & Hers and compounding pharmacies, citing safety concerns and misleading marketing practices.
/ 88 items
#LLY↓
FDA Commissioner Warns Against "Illegal Copycat" Weight-Loss Drugs
FDA takes aim at compounded weight-loss drugs like Hims' $49 Wegovy alternative, raising safety concerns over unapproved copycat medications flooding the market.
Hims & Hers Launches $49 Wegovy Alternative, Shaking Up Weight Loss Market
Hims & Hers offers compounded semaglutide pill at $49/month introductory price, significantly undercutting Novo Nordisk's $199 Wegovy brand-name treatment with same active ingredient.
Amgen Beats Q4 Expectations Despite FDA Drug Controversy
Amgen (AMGN) reports strong Q4 2025 earnings with $9.87B revenue, beating estimates. Company defies FDA request to withdraw Tavneos while advancing obesity drug MariTide through trials.
Eli Lilly Crushes Forecasts on Weight-Loss Drug Boom
Eli Lilly (LLY) beats Q4 expectations and projects strong 2026 growth driven by surging demand for Zepbound and Mounjaro, outpacing rival Novo Nordisk.
Novo Nordisk Expects Sales Drop in 2026 Amid Rising Competition
Novo Nordisk forecasts 5-13% sales decline for 2026 as Ozempic and Wegovy face intense competition from Eli Lilly and generics, plus US drug pricing pressures.